BioSpace News Archive

Aptevo Therapeutics Inc. today announced that the Company has earned a $10 million non-dilutive milestone payment related to 2021 sales of RUXIENCE®.

AiCuris acquires exclusive rights to develop and commercialize Hybridize’s program to prevent severe disease from BK virus (BKV) infections in immunocompromised patients.

Wave Life Sciences Ltd. announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Virtual 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 10:40 a.m. ET.

Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, announced with its shareholder, Grand Pharmaceutical Group Limited, that SIR-Spheres® Y-90 resin microspheres have been approved by the National Medical Products Administration for the treatment of patients with colorectal cancer liver metastases.

Elpiscience Biopharmaceuticals, Inc., a global clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer immunotherapies, announced that the Center of Drug Evaluation has cleared Elpiscience’s Investigational New Drug Application for ES002 to initiate a Phase I clinical trial in China.

Mirum Pharmaceuticals, Inc. announced that it will present during the SVB Leerink 11th Annual Global Healthcare Conference taking place virtually February 14-18, 2022.

Scopio Labs, provider of the world’s first full-field digital cell morphology solution, announced a $50M investment for its end-to-end hardware and software platform for digitizing, quantifying and analyzing hematology and other digital cytology samples.

Day Zero Diagnostics, Inc., an infectious disease diagnostics company harnessing the power of whole-genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, announced the completion of a $21M venture equity financing.

Invacare Corporation (NYSE: IVC) (“Invacare” or the “company”) announces that it will release its financial results for the fourth quarter and year ended December 31, 2021, after the market closes on Tuesday, March 8, 2022.

Sonnet BioTherapeutics Holdings, Inc. announced that data from preclinical studies of the company’s proprietary Fully Human Albumin Binding candidates, SON-1010, SON-1210, and SON-1410, will be presented at the upcoming American Association for Cancer Research Annual Meeting 2022, to be held April 8-13, in New Orleans, Louisiana.